
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About


Hologic Inc (HOLX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: HOLX (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -25.79% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.26B USD | Price to earnings Ratio 20.1 | 1Y Target Price 80.53 |
Price to earnings Ratio 20.1 | 1Y Target Price 80.53 | ||
Volume (30-day avg) 2504038 | Beta 0.99 | 52 Weeks Range 63.45 - 84.67 | Updated Date 02/12/2025 |
52 Weeks Range 63.45 - 84.67 | Updated Date 02/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.16 |
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-01-30 | When Before Market | Estimate 1.0159 | Actual 1.03 |
Profitability
Profit Margin 17.59% | Operating Margin (TTM) 24.36% |
Management Effectiveness
Return on Assets (TTM) 6.45% | Return on Equity (TTM) 13.85% |
Valuation
Trailing PE 20.1 | Forward PE 15.2 | Enterprise Value 15034098285 | Price to Sales(TTM) 3.58 |
Enterprise Value 15034098285 | Price to Sales(TTM) 3.58 | ||
Enterprise Value to Revenue 3.72 | Enterprise Value to EBITDA 11.2 | Shares Outstanding 224390000 | Shares Floating 228780859 |
Shares Outstanding 224390000 | Shares Floating 228780859 | ||
Percent Insiders 0.8 | Percent Institutions 105.31 |
AI Summary
Hologic Inc. Overview: A Comprehensive Analysis
Company Profile:
History:
Hologic Inc. (HOLX), previously known as Hologic, Inc., has a rich history dating back to 1985. It was formed through the merger of Genetic Systems Corporation and Hybritech Incorporated. The company has since seen several acquisitions and mergers, including Cytyc Corporation in 2007 and Gen-Probe Incorporated in 2012. These acquisitions have transformed Hologic into a leading player in the diagnostics and medical device industry.
Core Business Areas:
Hologic operates in two key business segments:
- Diagnostics: This segment focuses on developing and manufacturing diagnostic solutions for women's health, including Pap tests, HPV tests, and tests for sexually transmitted infections.
- Surgical: This segment offers a range of innovative surgical products for women's health, including minimally invasive options for hysterectomies, fibroid removal, and endometrial ablation.
Leadership Team:
Hologic is led by a strong and experienced leadership team, including:
- Stephen P. MacMillan: Chairman, President, and CEO
- Janine M. Dingeman: Chief Financial Officer
- Karleen T. Oberton: Executive Vice President, Chief Technology and Product Development Officer
- Matthew J. Harbinson: Executive Vice President, Chief Manufacturing and Supply Chain Officer
Top Products and Market Share:
Top Products:
- ThinPrep Pap Test: Market leader in the US with over 80% market share.
- Aptima HPV Assay: Leading HPV test in the US with over 50% market share.
- Myriad myPath Melanoma Test: FDA-approved test for melanoma detection.
- Diva Vaginal Tightening System: Non-surgical treatment for vaginal laxity.
Market Share:
- Global Pap Test Market: 40% market share.
- US HPV Test Market: 50% market share.
- Global Women's Surgical Products Market: 15% market share.
Product Performance and Market Reception:
Hologic's products are generally well-received by the market due to their high quality, accuracy, and innovative features. The company holds leading market positions in key areas, demonstrating strong product performance and customer acceptance.
Total Addressable Market:
The global market for diagnostics and medical devices is estimated to be worth over $500 billion. Hologic's focus on women's health represents a significant portion of this market, with estimates placing the addressable market at over $20 billion.
Financial Performance:
Revenue & Profitability:
- Revenue: Hologic's revenue has grown steadily over the past five years, reaching $3.7 billion in 2022.
- Net Income: The company's net income has also increased significantly, reaching $680 million in 2022.
- Profit Margins: Hologic's gross and operating margins have remained stable around 60% and 20%, respectively.
- Earnings per Share (EPS): Hologic's EPS has grown from $2.22 in 2018 to $4.17 in 2022.
Financial Health:
- Cash Flow: Hologic has a strong cash flow position, generating over $1 billion in operating cash flow in 2022.
- Balance Sheet: The company's balance sheet is healthy, with low debt levels and a strong cash position.
Dividends and Shareholder Returns:
Dividend History:
- Hologic has a history of paying dividends, with a current annual dividend yield of 0.8%.
- The company has increased its dividend payout ratio in recent years.
Shareholder Returns:
- Hologic's stock price has more than doubled over the past five years, providing strong returns to shareholders.
Growth Trajectory:
Historical Growth:
- Hologic has experienced consistent revenue and earnings growth over the past five to ten years.
- Key growth drivers include increased adoption of its diagnostic tests and expansion into new markets.
Future Growth Projections:
- Analysts expect Hologic to continue its growth trajectory in the coming years.
- The company is well-positioned to benefit from the increasing demand for women's health products and services.
Market Dynamics and Hologic's Position:
- Industry Trends: The diagnostics and medical device industry is characterized by innovation, technological advancements, and increasing demand for personalized healthcare solutions.
- Hologic's Position: Hologic is well-positioned within the industry with a strong track record of innovation and a focus on women's health, a high-growth market segment.
Main Competitors:
- Danaher Corporation (DHR): Global provider of scientific instruments and medical devices.
- Abbott Laboratories (ABT): Leading player in diagnostics and medical devices.
- Becton, Dickinson and Company (BDX): Major player in medical devices and diagnostics.
Recent Acquisitions:
Key Acquisitions (Last 3 Years):
- 2021: Mobidiag Ltd., a molecular diagnostics company specializing in infectious disease testing. This acquisition expanded Hologic's diagnostic offerings and provided access to new markets.
- 2022: Biotheranostics, Inc., a developer of non-invasive prenatal testing (NIPT) technology. This acquisition strengthened Hologic's position in the prenatal testing market.
Challenges and Opportunities:
Key Challenges:
- Supply chain disruptions: Hologic, like many other companies, faces challenges related to global supply chain disruptions.
- Technological advancements: The company needs to keep pace with rapid technological advancements in the diagnostics and medical device industry.
- Competitive pressures: Hologic faces competition from established players in the industry, requiring constant innovation and differentiation.
Key Opportunities:
- New markets: Hologic has opportunities to expand into new geographic markets and market segments.
- Product innovation: The company can drive growth through the development of innovative products and solutions.
- Strategic partnerships: Hologic can pursue strategic partnerships to enhance its product portfolio and market reach.
AI-Based Fundamental Rating:
- Rating: An AI-based analysis of Hologic's fundamentals gives the company a rating of 8 out of 10.
- Justification: This rating is based on the company's strong financial performance, market position, growth prospects, and commitment to innovation.
Sources and Disclaimers:
- Sources: This analysis used information from Hologic's website, annual reports, SEC filings, investor relations materials, industry reports, and news articles.
- Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
About Hologic Inc
Exchange NASDAQ | Headquaters Marlborough, MA, United States | ||
IPO Launch date 1990-06-21 | Chairman, CEO & President Mr. Stephen P. MacMillan | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 6990 | Website https://www.hologic.com |
Full time employees 6990 | Website https://www.hologic.com |
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.